NASDAQ:GHRS GH Research (GHRS) Stock Price, News & Analysis $25.96 -1.90 (-6.82%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$25.58 -0.38 (-1.48%) As of 06:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About GH Research Stock (NASDAQ:GHRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GH Research alerts:Sign Up Key Stats Today's Range$25.67▼$28.1350-Day Range$25.96▼$30.6452-Week Range$12.04▼$31.44Volume178,787 shsAverage Volume171,059 shsMarket Capitalization$1.78 billionP/E RatioN/ADividend YieldN/APrice Target$45.00Consensus RatingModerate Buy Company Overview GH Research plc is a clinical-stage biopharmaceutical company headquartered in Dublin, Ireland. Founded in 2018, the company focuses on developing novel therapies for psychiatric and neurological disorders, with an emphasis on treatments that may offer rapid effects. Its lead program, GH001, is an inhaled formulation of mebufotenin, also known as 5-MeO-DMT, being studied for treatment-resistant depression. GH Research is also developing additional formulations and delivery approaches based on mebufotenin, including the GH002 program. The company’s pipeline remains in clinical development, and it does not currently have marketed products. GH Research conducts its research and clinical development activities internationally, including in the United States and Europe. The company’s programs are intended for patients with significant unmet needs in psychiatric medicine, subject to the results of clinical trials and regulatory review.AI Generated. May Contain Errors. Read More GH Research Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreGHRS MarketRank™: GH Research scored higher than 54% of companies evaluated by MarketBeat, and ranked 416th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingGH Research has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialGH Research has a consensus price target of $45.00, representing about 73.3% upside from its current price of $25.96.Amount of Analyst CoverageGH Research has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GH Research's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($1.20) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GH Research is -25.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GH Research is -25.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGH Research has a P/B Ratio of 5.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GH Research's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.69% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 18.5, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently decreased by 2.00%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.63 News SentimentGH Research has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for GH Research this week, compared to 2 articles on an average week.Search Interest5 people have searched for GHRS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GH Research's insider trading history. Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GHRS Stock News HeadlinesGH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion OpportunitiesSeptember 20, 2026 | seekingalpha.comGH Research PLC (NASDAQ:GHRS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 13, 2026 | americanbankingnews.comWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starfighter aircraft, giving it a rare platform for high-speed flight testing, captive-carry missions and aerospace research. Its Wind Tunnel in the Sky concept exposes hardware to real high-speed atmospheric conditions, while new collaborations with Vaya Defense & Space and The Bionetics Corporation expand its reach into propulsion, hypersonic test articles and payload processing. FJET is also developing STARLAUNCH, an air-launched system targeting suborbital missions, positioning the company across testing, defense and launch.September 24 at 1:00 AM | Trading Wire (Ad)GH Research Files Q2 2026 Results and Updates Corporate PresentationAugust 6, 2026 | tipranks.comGH Research Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 6, 2026 | globenewswire.comWells Fargo Initiates GH Research at Overweight With $44 Price TargetJuly 29, 2026 | finance.yahoo.comWhy Psychedelic stocks are surging todayJuly 16, 2026 | finance.yahoo.comEli Lilly deal to buy AtaiBeckley boosts psychedelic stocksJuly 16, 2026 | msn.comSee More Headlines GHRS Stock Analysis - Frequently Asked Questions How have GHRS shares performed this year? GH Research's stock was trading at $12.70 at the beginning of 2026. Since then, GHRS stock has increased by 104.4% and is now trading at $25.96. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) issued its earnings results on Thursday, August, 6th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.06. When did GH Research IPO? GH Research (GHRS) raised $150 million in an initial public offering (IPO) on Tuesday, June 22nd 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. Who are GH Research's major shareholders? Top institutional shareholders of GH Research include Braidwell LP (0.30%) and Squarepoint Ops LLC (0.03%). How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GH Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that GH Research investors own include Baidu (BIDU), Bristol Myers Squibb (BMY), Zoom Communications (ZM), Atai Beckley (ATAI), CRISPR Therapeutics (CRSP) and Caesars Entertainment (CZR). Company Calendar Last Earnings8/06/2026Today9/24/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 GHRS's financial health is in the Green zone, according to TradeSmith. GHRS has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GHRS CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees73Year Founded2018Price Target and Rating Average Price Target for GH Research$45.00 High Price Target$65.00 Low Price Target$39.00 Potential Upside/Downside+73.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.86% Return on Assets-20.12% Debt Debt-to-Equity RatioN/A Current Ratio28.70 Quick Ratio28.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.51 per share Price / Book5.76Miscellaneous Outstanding Shares68,609,000Free Float40,068,000Market Cap$1.78 billion OptionableOptionable Beta1.27 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:GHRS) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersEveryone remembers January's silver spike. Then what?Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...i2i Marketing Group, LLC | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
